Prexton Therapeutics SA:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Prexton Therapeutics SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11199
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:18
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Prexton Therapeutics SA (Prexton) is a developer of drugs for Parkinson’s disease and other brain disorders. The company designs and develops mGluR4 positive allosteric modulator compounds for the treatment for Parkinson’s disease. It also develops positive allosteric modulators, or PAMs to increase mGluR4 activity. The company’s product pipeline includes new chemical entities, which target mGluR4 receptors that cater to medical need for the improvement of symptomatic control in Parkinson’s disease. It also develops its lead compound Foliglurax, which is in phase II clinical trial. Prexton is headquartered in Geneva, Switzerland.

Prexton Therapeutics SA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Prexton Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Prexton Therapeutics SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Prexton Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Prexton Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Prexton Therapeutics SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Prexton Therapeutics SA, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Prexton Therapeutics Raises USD31.2 Million in Series B Venture Financing 10
Prexton Therapeutics Raises USD10 Million in Series A Venture Financing 12
Prexton Therapeutics Raises US$2.6 Million In Seed Financing 13
Licensing Agreements 14
Domain Therapeutics Enters Into Option For Licensing Agreement With Prexton Therapeutics 14
Prexton Therapeutics SA – Key Competitors 15
Prexton Therapeutics SA – Key Employees 16
Prexton Therapeutics SA – Locations And Subsidiaries 17
Head Office 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18

List of Tables
Prexton Therapeutics SA, Pharmaceuticals & Healthcare, Key Facts 2
Prexton Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Prexton Therapeutics SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Prexton Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Prexton Therapeutics SA, Deals By Therapy Area, 2012 to YTD 2018 8
Prexton Therapeutics SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Prexton Therapeutics Raises USD31.2 Million in Series B Venture Financing 10
Prexton Therapeutics Raises USD10 Million in Series A Venture Financing 12
Prexton Therapeutics Raises US$2.6 Million In Seed Financing 13
Domain Therapeutics Enters Into Option For Licensing Agreement With Prexton Therapeutics 14
Prexton Therapeutics SA, Key Competitors 15
Prexton Therapeutics SA, Key Employees 16

List of Figures
Prexton Therapeutics SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Prexton Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Prexton Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Prexton Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Prexton Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Prexton Therapeutics SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Prexton Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Prexton Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Prexton Therapeutics SA:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Breg Inc-医療機器分野:企業M&A・提携分析
    Summary Breg Inc (Breg) is a medical device company that manufactures and distributes cold therapy products. The company offers products, which include cold therapy products, hip braces, elbow or wrist braces, knee braces, shoulder braces, spine braces, ankle braces, home therapy kits, and others. I …
  • Centauri Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Centauri Therapeutics Ltd (Centauri Therapeutics) is a biotechnology company that discovers and develops novel molecules for life threatening diseases. The company uses alphamer technology to develop anti-infective therapeutics. Its alphamer technology is based on programmable immunity in wh …
  • Greggs Plc:企業の戦略・SWOT・財務情報
    Greggs Plc - Strategy, SWOT and Corporate Finance Report Summary Greggs Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Vivendi SA (VIV):企業の財務・戦略的SWOT分析
    Vivendi SA (VIV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Taiga Building Products Ltd (TBL):企業の財務・戦略的SWOT分析
    Taiga Building Products Ltd (TBL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • CritiTech Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary CritiTech Inc (CritiTech) is a pharmaceutical contract development manufacturing organization that specializes in particle engineering, material characterization, analytical testing, early stage drug development, pre-clinical and clinical manufacturing. The company uses Spray Drying and Supe …
  • Teijin Limited:企業の戦略・SWOT・財務情報
    Teijin Limited - Strategy, SWOT and Corporate Finance Report Summary Teijin Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Suzlon Energy Ltd (SUZLON)-エネルギー分野:企業M&A・提携分析
    Summary Suzlon Energy Ltd (Suzlon) is a renewable energy solutions provider and manufacturer of wind turbines. It designs, develops and manufactures wind turbines and related components such as rotor blades, control panels, nacelle covers, tubular towers, generators and gearboxes. Suzlon also provid …
  • Exelon Corporation (EXC)-エネルギー分野:企業M&A・提携分析
    Summary Exelon Corporation (Exelon) is a utility services holding company operating across the energy value chain comprising power generation, distribution, transmission and energy sales. It generates electricity from diverse sources, including nuclear, fossil fuels and renewable energy. Exelon deli …
  • Exact Sciences Corp (EXAS):企業の財務・戦略的SWOT分析
    Exact Sciences Corp (EXAS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Egyptian General Petroleum Corporation:石油・ガス:M&Aディール及び事業提携情報
    Summary Egyptian General Petroleum Corporation (EGPC), formerly General Petroleum Authority, is engaged in the oil and gas exploration services. The company is engaged in the refining, production, drilling, transportation and storage of crude oil; production of lubricants and greases; provides man p …
  • Frequency Electronics Inc:企業の戦略・SWOT・財務情報
    Frequency Electronics Inc - Strategy, SWOT and Corporate Finance Report Summary Frequency Electronics Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Pearson plc (PSON):企業の財務・戦略的SWOT分析
    Pearson plc (PSON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • AdvantEdge Healthcare Solutions Inc-医療機器分野:企業M&A・提携分析
    Summary AdvantEdge Healthcare Solutions Inc (AdvantEdge) is a healthcare service provider that offers medical billing, coding and revenue cycle management solutions. The center’s solutions include medical billing, coding, reporting, dashboards and business intelligence, consulting and practice manag …
  • Telecom Plus plc (TEP)-エネルギー分野:企業M&A・提携分析
    Summary Telecom Plus plc (Telecom Plus), trading as The Utility Warehouse, is a provider of utility services. The company provides diversified utility services, including fixed and mobile telephony, gas, electricity, cashback card services and broadband services. It provides benefit of single monthl …
  • BASF India Ltd (BASF):企業の財務・戦略的SWOT分析
    Summary BASF India Ltd (BASF) a subsidiary of BASF SE is a chemical company that manufactures and distributes specialty chemicals, performance products, plastics and crop protection products. The company’s chemical products include intermediates, monomers and petrochemicals. Its performance products …
  • Linamar Corporation (LNR):企業の財務・戦略的SWOT分析
    Linamar Corporation (LNR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Armetheon Inc-製薬・医療分野:企業M&A・提携分析
    Summary Armetheon Inc (Armetheon) is a drug development company that develops novel small molecule drugs for treatment of cardiovascular diseases with high unmet medical need. The company develops anticoagulants and antibiotics that make use of the antibiotic resistance mechanisms to provide bacteri …
  • Nomura Holdings, Inc.:企業の戦略・SWOT・財務情報
    Nomura Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Nomura Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Dominium S.A.:企業の戦略・SWOT・財務情報
    Dominium S.A. - Strategy, SWOT and Corporate Finance Report Summary Dominium S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆